Cargando…

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials

PURPOSE: The addition of bisphosphonates to adjuvant therapy improves survival in postmenopausal breast cancer (BC) patients. We report a meta-analysis of four randomised trials of neoadjuvant chemotherapy (CT) +/− zoledronic acid (ZA) in stage II/III BC to investigate the potential for enhancing th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kroep, J.R., Charehbili, A., Coleman, R.E., Aft, R.L., Hasegawa, Y., Winter, M.C., Weilbaecher, K., Akazawa, K., Hinsley, S., Putter, H., Liefers, G.J., Nortier, J.W.R., Kohno, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928630/ https://www.ncbi.nlm.nih.gov/pubmed/26722766 http://dx.doi.org/10.1016/j.ejca.2015.10.011

Ejemplares similares

Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?
por: Charehbili, Ayoub, et al.
Publicado: (2013)

Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer
por: Aft, R L, et al.
Publicado: (2012)

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, Stefanie, et al.
Publicado: (2019)

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
por: de Groot, A. F., et al.
Publicado: (2019)

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, S., et al.
Publicado: (2015)

Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid
por: Aft, Rebecca
Publicado: (2012)

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer
por: Coleman, R E, et al.
Publicado: (2010)

Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer
por: Hagenaars, Sophie C., et al.
Publicado: (2021)

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)
por: Hasegawa, Yoshie, et al.
Publicado: (2015)

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies
por: Vriens, Birgit E.P., et al.
Publicado: (2017)

Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – An AZURE (BIG 01/04) sub-study
por: Wilson, Caroline, et al.
Publicado: (2016)

Using a quality of life (QoL)-monitor: preliminary results of a randomized trial in Dutch patients with early breast cancer
por: Lugtenberg, R. T., et al.
Publicado: (2020)

Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma
por: Byrum, M.L., et al.
Publicado: (2016)

Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid
por: Lefley, DV, et al.
Publicado: (2008)

The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis
por: Hadji, P., et al.
Publicado: (2012)

Cross-cultural comparison of breast cancer patients’ Quality of Life in the Netherlands and Japan
por: Fischer, M. J., et al.
Publicado: (2017)

Illness Perceptions and Quality of Life in Patients with Non-Small-Cell Lung Cancer: A 3-Month Follow-Up Pilot Study
por: Vollmann, Manja, et al.
Publicado: (2020)

Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial
por: Lipplaa, Astrid, et al.
Publicado: (2019)

Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid
por: Ottewell, PD, et al.
Publicado: (2008)

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
por: Engels, C. C., et al.
Publicado: (2015)

Higher ER load is not associated with better outcome in stage 1–3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer
por: Noordhoek, I., et al.
Publicado: (2019)

The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer
por: Nout, R. A., et al.
Publicado: (2007)

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
por: de Groot, Stefanie, et al.
Publicado: (2020)

Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial
por: Crocamo, Susanne, et al.
Publicado: (2019)

Substrate and flow characteristics associated with White Sturgeon recruitment in the Columbia River Basin
por: Hatten, J.R., et al.
Publicado: (2018)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
por: Jagdev, S P, et al.
Publicado: (2001)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
por: de Groot, Stefanie, et al.
Publicado: (2015)

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
por: Veltman, J D, et al.
Publicado: (2010)

The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells
por: Brown, Hannah K, et al.
Publicado: (2011)

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
por: Coleman, R.E., et al.
Publicado: (2018)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Current perspectives on skeletal health and cancer progression across the disease continuum in breast cancer—the role of bisphosphonates
por: Aft, R
Publicado: (2012)

Zoledronic acid in the management of metastatic bone disease
por: Polascik, Thomas J, et al.
Publicado: (2008)

Zoledronic acid for neonatal subcutaneous fat necrosis
por: Di Bari, Jeremy A., et al.
Publicado: (2017)

Zoledronate rescues immunosuppressed monocytes in sepsis patients
por: Raffray, Loïc, et al.
Publicado: (2019)

Acute Iridocyclitis Associated With Intravenous Zoledronic Acid: A Case Report
por: Ankireddypalli, Anvitha R, et al.
Publicado: (2023)

Management of osteoporosis in the aging male: Focus on zoledronic acid
por: Piper, Paul K, et al.
Publicado: (2009)

Stathmin is involved in the cooperative effect of Zoledronic acid and gefitinib on bone homing breast cancer cells in vitro
por: Oda, Miki, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1rjdjlm15ffj7r75vdlnfi8tk5